within Pharmacolibrary.Drugs.ATC.N;

model N05AL04
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.42,
    Cl             = 2.3333333333333332e-05,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0029,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.013333333333333334,
    Tlag           = 0,            
    Vdp             = 0.0011,
    k12             = 1.3,
    k21             = 1.3
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N05AL04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Remoxipride is an atypical antipsychotic drug, primarily acting as a dopamine D2 receptor antagonist. It was used for the treatment of schizophrenia and related psychotic disorders, but has since been withdrawn from the market worldwide due to reports of aplastic anemia.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after single oral dose administration.</p><h4>References</h4><ol><li><p>von Bahr, C, et al., &amp; Widman, M (1990). Clinical pharmacokinetics of remoxipride. <i>Acta psychiatrica Scandinavica. Supplementum</i> 358 41–44. DOI:<a href=\"https://doi.org/10.1111/j.1600-0447.1990.tb05284.x\">10.1111/j.1600-0447.1990.tb05284.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1978486/\">https://pubmed.ncbi.nlm.nih.gov/1978486</a></p></li><li><p>Widerlöv, E, et al., &amp; Nilsson, MI (1991). Pharmacokinetics and effects on prolactin of remoxipride in patients with tardive dyskinesia. <i>Psychopharmacology</i> 103(1) 46–49. DOI:<a href=\"https://doi.org/10.1007/BF02244072\">10.1007/BF02244072</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1672458/\">https://pubmed.ncbi.nlm.nih.gov/1672458</a></p></li><li><p>Movin-Osswald, G, et al., &amp; Nilsson, LB (1993). The pharmacokinetics of remoxipride and metabolites in patients with various degrees of renal function. <i>British journal of clinical pharmacology</i> 35(6) 615–622. DOI:<a href=\"https://doi.org/10.1111/j.1365-2125.1993.tb04191.x\">10.1111/j.1365-2125.1993.tb04191.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8329289/\">https://pubmed.ncbi.nlm.nih.gov/8329289</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N05AL04;
